Paper28964591
A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Rett Syndrome.
Glaze DG and 10 others. Pediatr Neurol, 2017. Cited by 81 papers, by iCite.
Cite this record
ConductScience Library. A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Rett Syndrome. Papers, record 28964591. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28964591
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Neuroprotective Agents | Major topic |
| Oligopeptides | Major topic |
| Rett Syndrome | Major topic |
| Adolescent | |
| Adult | |
| Female | |
| Humans | |
| Male | |
| Young Adult | |
| Cohort Studies | |
| Dose-Response Relationship, Drug | |
| Double-Blind Method | |
| Treatment Outcome | |
| Glutamates |
Source PubMed
Cited by63
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 81 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42577214 | Characteristics of adult individuals with Rett syndrome treated or untreated with trofinetide in the United States. | Front Neurol | 2026 | https://conductscience.org/library/papers/42577214 | PubMed |
| 42563928 | Expert Consensus on Real-World Use of Trofinetide for Rett Syndrome Using a Modified Delphi Method. | Ann Child Neurol Soc | 2026 | https://conductscience.org/library/papers/42563928 | PubMed |
| 42530159 | Mapping Trofinetide Polypharmacology in Rett Syndrome: A Multi-Stage Computational Analysis. | J Comput Chem | 2026 | https://conductscience.org/library/papers/42530159 | PubMed |
| 42383019 | Minimum data requirements and automated preprocessing for reliable EEG biomarkers in Rett syndrome. | Front Neurol | 2026 | https://conductscience.org/library/papers/42383019 | PubMed |
| 42111068 | Clinical experience using trofinetide in Rett syndrome and related MECP2 diagnosis at the children's hospital of Philadelphia post approval. | Front Neurol | 2026 | https://conductscience.org/library/papers/42111068 | PubMed |
| 41501636 | Longitudinal Rett syndrome behaviour questionnaire scores and their associations with genotype and trajectories of mobility, weight and seizure frequency status. | J Neurodev Disord | 2026 | https://conductscience.org/library/papers/41501636 | PubMed |
| 40882535 | Natural history of epilepsy in FOXG1 Syndrome. | Epilepsy Res | 2025 | https://conductscience.org/library/papers/40882535 | PubMed |
| 40880843 | Symptom Onset in Classic Rett Syndrome: Analysis of Initial Clinical Severity Scale Entries. | Ann Child Neurol Soc | 2025 | https://conductscience.org/library/papers/40880843 | PubMed |
| 40595330 | AI-enabled drug prediction and gene network analysis reveal therapeutic use of vorinostat for Rett Syndrome in preclinical models. | Commun Med (Lond) | 2025 | https://conductscience.org/library/papers/40595330 | PubMed |
| 40138183 | A Blueprint for Translational Precision Medicine in Autism Spectrum Disorder and Related Neurogenetic Syndromes. | J Child Adolesc Psychopharmacol | 2025 | https://conductscience.org/library/papers/40138183 | PubMed |
| 39709426 | International workshop: what is needed to ensure outcome measures for Rett syndrome are fit-for-purpose for clinical trials? June 7, 2023, Nashville, USA. | Trials | 2024 | https://conductscience.org/library/papers/39709426 | PubMed |
| 39692836 | Population Pharmacokinetic Modeling to Support Trofinetide Dosing for the Treatment of Rett Syndrome. | Adv Ther | 2025 | https://conductscience.org/library/papers/39692836 | PubMed |
| 39669590 | Trofinetide approved for children and adults with Rett syndrome (RTT): A therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG). | Genet Med Open | 2024 | https://conductscience.org/library/papers/39669590 | PubMed |
| 39641900 | Drug Treatments for Neurodevelopmental Disorders: Targeting Signaling Pathways and Homeostasis. | Curr Neurol Neurosci Rep | 2024 | https://conductscience.org/library/papers/39641900 | PubMed |
| 39525048 | Profile of Trofinetide in the Treatment of Rett Syndrome: Design, Development and Potential Place in Therapy. | Drug Des Devel Ther | 2024 | https://conductscience.org/library/papers/39525048 | PubMed |
| 39516357 | Physiologically-Based Pharmacokinetic Modeling of Trofinetide in Moderate Renal Impairment for Phase 1 Clinical Study Dose Selection with Model Validation. | Eur J Drug Metab Pharmacokinet | 2025 | https://conductscience.org/library/papers/39516357 | PubMed |
| 39455915 | Associations between genotype, phenotype and behaviours measured by the Rett syndrome behaviour questionnaire in Rett syndrome. | J Neurodev Disord | 2024 | https://conductscience.org/library/papers/39455915 | PubMed |
| 39440617 | Clinical trials for Lennox-Gastaut syndrome: Challenges and priorities. | Ann Clin Transl Neurol | 2024 | https://conductscience.org/library/papers/39440617 | PubMed |
| 39251501 | Rett Syndrome: The Emerging Landscape of Treatment Strategies. | CNS Drugs | 2024 | https://conductscience.org/library/papers/39251501 | PubMed |
| 39020317 | Is trofinetide a future treatment for Rett syndrome? A comprehensive systematic review and meta-analysis of randomized controlled trials. | BMC Med | 2024 | https://conductscience.org/library/papers/39020317 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28964591
GET https://conductscience.org/api/papers/v1/28964591/cited_by?page=2